Wikipedia

Sinopharm Group

Not to be confused with Sinopharm, the short name of the parent company China National Pharmaceutical Group.

Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.

Sinopharm Group
Company typepublic
unlisted(A share)
SEHK: 1099(H share)
ISINCNE100000FN7
IndustryPharmaceutical
Founded
  • 1998 (predecessor)
  • 2003
FounderChina National Pharmaceutical Group
HeadquartersSinopharm Plaza,
Shanghai
,
China
Area served
China
Key people
  • Wei Yulin (Chairman)
  • Chen Qiyu (Vice-Chairman)
  • Li Zhiming (President)
RevenueIncrease CN¥227.069 billion (2015)
Increase CN¥9.169 billion (2015)
Increase CN¥3.761 billion (2015)
Total assetsIncrease CN¥138.267 billion (2015)
Total equityIncrease CN¥30.052 billion (2015)
OwnerSinopharm Industrial Investment (56.79%)
ParentSinopharm Industrial Investment
SubsidiariesSinopharm CNMC
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Hong Kong Financial Reporting Standards[1]
Sinopharm Group Co., Ltd.
Simplified Chinese国药控股股份有限公司
Traditional Chinese國藥控股股份有限公司
Literal meaningSinopharm Holding Joint-Stock Limited Company
Transcriptions
Sinopharm Group
Simplified Chinese国药控股
Traditional Chinese國藥控股
Literal meaningSinopharm Holding
Transcriptions
Second alternative Chinese name
Simplified Chinese国控股份有限公司
Traditional Chinese國控股份有限公司
Transcriptions

Its H shares were listed on the Hong Kong Stock Exchange in 2009,[2] with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.

Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list.[3]

COVID-19 Vaccine development

edit
Main article: Sinopharm BIBP COVID-19 vaccine

The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[4] the Sinopharm COVID-19 vaccine,[5] or BIBP vaccine,[5][6][7] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[8] The BIBP vaccine shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19.[9]

Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the BIBP vaccine is 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[10] In December 2020, the UAE previously announced interim results showing 86% efficacy.[11] While mRNA vaccines showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[12]

The BIBP vaccine is being used in vaccination campaigns by certain countries in Asia,[13][14][15] Africa,[16][17][18] South America,[19][20][21] and Europe.[22][23][24] Sinopharm was expected to produce one billion doses of the BIBP vaccine in 2021.[25] On 7 May 2021, the World Health Organization approved the vaccine for use in COVAX.[14][26]

See also

edit

References

edit
  1. ^ "2015 Annual Report" (PDF). Sinopharm Group. Hong Kong Stock Exchange. 25 April 2016. Retrieved 22 November 2016.
  2. ^ "China's Sinopharm gets OK for $1 bln HK IPO". Reuters. 2009-07-29. Retrieved 2020-11-14.
  3. ^ "Sinopharm Group". Forbes. Retrieved 2020-11-14.
  4. ^ Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. (January 2021). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. 21 (1): 39–51. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304. PMID 33069281.
  5. ^ a b "The Sinopharm COVID-19 vaccine: What you need to know". World Health Organization. 10 May 2021. Retrieved 5 July 2021.
  6. ^ Nguyen S (5 June 2021). "Coronavirus: Vietnam approves Sinopharm's vaccine, but will people take it?". South China Morning Post. Retrieved 5 July 2021.
  7. ^ Lahiri T, Li J (16 June 2021). "What we now know about the efficacy of China's Covid-19 vaccines". Quartz. Retrieved 5 July 2021.
  8. ^ "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. 2020-11-19. Retrieved 2020-12-09.
  9. ^ Corum, Jonathan; Zimmer, Carl (2021-04-26). "How the Sinopharm Vaccine Works". The New York Times. ISSN 0362-4331. Retrieved 2021-04-29.
  10. ^ Kaabi, Nawal Al; Zhang, Yuntao; Xia, Shengli; et al. (May 26, 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. 326 (1): 35–45. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
  11. ^ "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. 9 December 2020. Retrieved 2020-12-13.
  12. ^ "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 2020-12-09. Retrieved 2020-12-09.
  13. ^ Liu R (2020-12-31). "China gives its first COVID-19 vaccine approval to Sinopharm". Reuters. Retrieved 2020-12-31.
  14. ^ a b Turak, Natasha (2021-01-18). "The UAE is on track to have half its population vaccinated by the end of March". CNBC. Retrieved 2021-01-21.
  15. ^ Dawn.com (2021-02-02). "PM Imran kicks off Pakistan's Covid-19 vaccination drive". DAWN.COM. Retrieved 2021-02-03.
  16. ^ "Sisi says Egypt to begin COVID-19 vaccinations on Sunday". Reuters. 2021-01-24. Retrieved 2021-01-24.
  17. ^ Dumpis, Toms (2021-01-27). "Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine". Morocco World News. Retrieved 2021-01-28.
  18. ^ "Zimbabwe starts administering China's Sinopharm vaccines". thestar.com. 2021-02-18. Retrieved 2021-02-20.
  19. ^ "Argentina autoriza la vacuna china Sinopharm para mayores de 60 años". El Comercio. 25 March 2021. Retrieved 2021-03-26.
  20. ^ Aquino, Marco (2021-02-10). "'The best shield': Peru launches inoculation drive with Sinopharm vaccine". Reuters. Retrieved 2021-02-10.
  21. ^ "Bolivia begins inoculation with Sinopharm jabs | The Star". www.thestar.com.my. Retrieved 2021-02-28.
  22. ^ "Serbia Becomes First European Nation To Use China's Sinopharm Vaccine". Radio Free Europe/Radio Liberty. 20 January 2021. Retrieved 2021-01-21.
  23. ^ "Hungary first EU nation to use China's Sinopharm vaccine against COVID". euronews. 2021-02-24. Retrieved 2021-02-26.
  24. ^ "Belarus begins COVID-19 vaccinations with Chinese shots". eng.belta.by. 2021-03-15. Retrieved 2021-03-16.
  25. ^ "Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World. 2021-02-05. Retrieved 2021-02-28.
  26. ^ Taylor, Adam (7 May 2021). "WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine". The Washington Post. Retrieved 7 May 2021.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sinopharm_Group&oldid=1243591926"